Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Kedudukan dalam Saham #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Harga Saham
$17.64
Modal Pasaran
$32.65B
Perubahan (1 hari)
-3.24%
Perubahan (1 tahun)
-23.70%
Negara
JP
Perdagangan Daiichi Sankyo Company, Limited (DSNKY)

Kategori

Nisbah P/E bagi Daiichi Sankyo Company, Limited (DSNKY)
Nisbah P/E pada March 2026 TTM: 17.13
Menurut laporan kewangan dan harga saham terkini Daiichi Sankyo Company, Limited, nisbah P/E semasa (TTM) ialah 17.13. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 44.58.
Sejarah nisbah P/E bagi Daiichi Sankyo Company, Limited dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 17.13 -23.91%
2025 22.51 -49.50%
2024 44.58 -47.34%
2023 84.66 10.38%
2022 76.70 -6.85%
2021 82.34 120.64%
2020 37.32 -2.53%
2019 38.29 -0.84%
2018 38.61 22.65%
2017 31.48 50.17%
2016 20.96 403.01%
2015 4.17 -79.24%
2014 20.08 9.51%
2013 18.33 -82.07%
2012 102.24 534.14%
2011 16.12 -45.26%
2010 29.45 -643.67%
2009 -5.42 -124.90%
2008 21.76 -35.05%
2007 33.50 49.10%
2006 22.47 0.07%
2005 22.45 9.57%
2004 20.49 -2.12%
2003 20.94 -26.72%
2002 28.57 -7.80%
2001 30.99 81.88%
2000 17.04 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
42.86 150.24%
US
28.47 66.20%
GB
21.88 27.76%
US
92.55 440.34%
US
20.85 21.73%
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.